Jaguar Animal Health, Inc. JAGX
7.70
0.64
9.07%
as of 25 Sep
- Market cap
- $3.8M
- P/E
- 0.1×
Follow JAGX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.37 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.31 | 3.40 | 2.83 | 4.49 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(6.82) | 11.38 | (5.94) | (11.30) | |
P/B ratio |
7.40 | 0.00 | 0.00 | 28.26 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.28 | 3.57 | 3.81 | 5.19 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.32) | (13.99) | (1.85) | (2.35) | |
EV/FCF |
(4.83) | (12.82) | (1.80) | (2.29) | |
Quick Ratio |
0.27 | 0.25 | 0.23 | 0.14 | |
Current Ratio |
0.69 | 0.50 | 0.50 | 0.81 | |
Net Debt/EBITDA |
0.73 | 0.09 | (0.35) | (0.62) | |
Debt/Assets |
5.05% | 29.59% | 39.36% | 15.46% | |
Debt/Equity |
0.35 | (0.70) | (0.81) | 1.75 | |
Asset Turnover |
0.67 | 0.67 | 0.25 | 0.22 | |
Operating CF/Net income |
0.42 | (1.26) | 0.24 | 0.49 | |
Capex/Depreciation |
0.00 | 0.00 | (0.06) | (0.10) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
272.33% | 19.38% | 442.44% | 118.65% | |
Selling, General and Administrative Expense of Revenue |
363.67% | 24.68% | 221.45% | 198.86% | |
Intangible Assets out of Total Assets |
0.44 | 0.42 | 0.42 | 0.35 | |
Share Based Compensation of Revenue |
13.96% | 0.76% | 3.59% | 4.38% | |
Graham Net Nets |
(0.32) | (0.33) | (1.12) | (0.30) | |
Graham Number |
128.48 | 390.93 | 2,379.49 | 0.00 | |
Earnings Yield |
268.05% | (114.19%) | (162.19%) | (138.94%) | |
Free Cash Flow Yield |
(20.25%) | (8.19%) | (74.76%) | (50.35%) | |
Revenue per Share |
1.51 | 39.30 | 48.50 | 71.20 | |
Operating CF per Share |
(6.60) | 17.12 | (82.28) | (108.29) | |
Capex per Share |
0.00 | 0.00 | (0.61) | (1.25) | |
Free Cash Flow per Share |
(6.60) | 17.12 | (82.89) | (109.54) | |
Cash per Share |
8.14 | 19.51 | 117.42 | 81.46 | |
Shareholders Equity per Share |
6.08 | (30.54) | (280.18) | 100.67 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.08 | (30.54) | (280.18) | 100.67 | |
Free Cash Flow |
(5.34) | 8.83 | (5.53) | (4.74) | |
Working Capital |
(7.85) | (20.48) | (20.31) | (6.72) | |
Capital Expenditures |
— | — | (0.04) | (0.05) | |
Net Current Asset Value |
(11.74) | (32.98) | (36.67) | (15.71) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.02 | |
Net Profit Margin |
(1,036.82%) | (34.60%) | (717.22%) | (308.21%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.76 | 0.83 | 1.67 | 1.41 | |
Average Payables |
5.71 | 5.99 | 6.99 | 6.50 | |
Average Inventory |
9.02 | 9.19 | 9.47 | 10.15 | |
Average Assets |
41.23 | 44.45 | 45.87 | 53.97 | |
Average Common Equity |
4.66 | (7.46) | (7.34) | 7.49 |
Columns are period end dates